TrialAssure News

TrialAssure Amplifies Clinical Trial Transparency Functionality with the Release of REGISTRY 2.5

TrialAssure Amplifies Clinical Trial Transparency Functionality with the Release of REGISTRY 2.5

Canton, Mich. (April 17, 2019) – TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the launch of TrialAssure REGISTRY 2.5, the latest iteration of TrialAssure’s premiere clinical trial registration and disclosure reporting application with a configurable workflow engine that allows clients to augment regulatory intelligence for global registries.

Groundbreaking Transparency Application that Anonymizes Patient Data in Clinical Trials Launched by TrialAssure

Groundbreaking Transparency Application that Anonymizes Patient Data in Clinical Trials Launched by TrialAssure

Canton, Mich. (February 27, 2019) – TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the limited release of ANONYMIZE DS, an all-new software-as-a-service (SaaS) application that allows sponsors to anonymize clinical trial data automatically. This exclusive application will be discussed during a presentation this afternoon by Zach Weingarden at the PhUSE Connect 2019 Data-Driven Science conference in Baltimore, Maryland.

TrialAssure® Announces New Applications in its Product Pipeline to Build The Ultimate Transparency Suite™

TrialAssure® Announces New Applications in its Product Pipeline to Build The Ultimate Transparency Suite™

Canton, Mich. (August 13, 2018) – TrialAssure® – a global company focused on providing clinical trial transparency solutions – announced today its pipeline of new applications to create The Ultimate Transparency Suite ™. TrialAssure’s expanded offering will consist of five distinct, integrated products that have been built from the ground up within the company to assist pharmaceutical and clinical research teams achieve compliance with global transparency regulations.